| Date |
Event |
Presentation |
Speakers |
|
October 28, 2013
|
Tumor Immunology and Immunotherapy
|
Disease associated antigens as targets for cancer immunosurvellance and candidates for prophylactic cancer vaccines
|
Olivera J. Finn
|
|
May 5, 2011
|
Biologic Therapies Summit IV: Current Agents and Future Targets
|
Combination Nonbiologic DMARDS | A Cost- Effective Alternative in RA Is Logical
|
Larry Moreland
|
|
|
|
Lessons from Granulomatous Infections
|
Joanne L. Flynn
|
|
February 26, 2011
|
Immunity in the Respiratory Tract: Challenges of the Lung Environment (X6)
|
Vaccines Inducing Pathogen-Specific Lung Immunity | Balancing Mucosal Immunity in a Vaccine Context
|
Jay K. Kolls
|
|
February 26, 2011
|
Mucosal Biology: A Fine Balance between Tolerance and Immunity (X5)
|
Immunity in Respiratory Tract (X6) | Balancing Mucosal Immunity in a Vaccine Context
|
Jay K. Kolls
|
|
November 30, 2010
|
Tumor Immunology in Conjunction with the Cancer Immunology Working Group of the AACR
|
Immunoprevention based on tumor associated antigens
|
Olivera J. Finn
|
|
|
|
Session 2: Premalignant Lesions and Prevention
|
Olivera J. Finn
|
|
|
|
Polarized dendritic cells in cancer therapy: Getting dendritic cells to lymph nodes and effector cells to tumors
|
Pawel Kalinski
|
|
|
|
Treg depletion and restoration of multifunctional T cell responses in patients with cancer
|
Theresa L. Whiteside
|
|
|
|
Session 8: Regulation of Immune Responses in Cancer: A Translational Paradigm
|
Theresa L. Whiteside
|
|
November 30, 2010
|
Tumor Immunology: Basic and Clinical Advances in Conjunction with the Cancer Immunology Working Group of the AACR
|
Immunoprevention based on tumor associated antigens
|
Olivera J. Finn
|
|
|
|
Session 1: Premalignant Lesions and Prevention
|
Olivera J. Finn
|
|
|
|
Polarized dendritic cells in cancer therapy: Getting dendritic cells to lymph nodes and effector cells to tumors
|
Pawel Kalinski
|
|
|
|
Treg depletion and restoration of multifunctional T cell responses in patients with cancer
|
Theresa L. Whiteside
|
|
|
|
Session 7: Regulation of Immune Responses in Cancer: A Translational Paradigm
|
Theresa L. Whiteside
|
|
October 3, 2010
|
4th Vaccine and ISV Annual Global Congress
|
Cancer vaccines: a tractable solution for an intractable problem | Session 3
|
Olivera J. Finn
|
|
October 3, 2010
|
From Fetomaternal Tolerance to Immunomodulatory Properties of Placenta-Derived Cells in Cell Therapy
|
SESSION III: Stem cell biology and immunological characteristics of cells from different placental regions
|
Stephen Strom
|
|
|
|
Amnion-derived cells to treat liver disease
|
Stephen Strom
|
|
August 18, 2009
|
Second Annual Pre-Clinical/Clinical Development of Immunotherapies and Vaccines
|
A Systematic Approach to Biomarker Discovery: Preamble to “iSBTc-FDA Taskforce on Immunotherapy Biomarkers”
|
Lisa H. Butterfield
|
|
|
|
Expert Panel Discussion: Commonalities and Lessons Learned from Infectious Disease and Cancer Immunotherapy and Vaccine/Immunotherapy Development Programs
|
Robert J. Binder
|
|
December 4, 2008
|
BIT Life Sciences 2nd Annual World Congress of Gene-2008 (WCG 2008)
|
Genetic Mechanism with Huntington Disease Patients:Track 2-5
|
Gettig Elizabeth
|
|
|
|
Genetic Mechanism with Huntington Disease Patients :Track 2-5
|
Gettig Elizabeth
|
|
August 18, 2008
|
Systems Integration in Biodefense
|
Building an Effective Partnership between the Private Sector and Government for Biodefense Countermeasure Development
|
Bradley T. Smith
|
|
May 30, 2008
|
ASCO Annual'08 Meeting
|
lymphoma and plasma cell disorders-- Prevention and Treatment of Bone Disease in Myeloma (M21)
|
G. David Roodman
|
|
|
|
meet the professor sessions-- Prevention and Treatment of Bone Disease in Myeloma (M21)
|
G. David Roodman
|
|
April 8, 2008
|
Molecular Evolution as a Driving Force in Infectious Diseases
|
Workshop
|
Elodie Ghedin
|
|
April 8, 2008
|
Molecular Evolution as a Driving Force in Infectious Diseases
|
Workshop
|
Elodie Ghedin
|
|
April 8, 2008
|
Molecular Evolution as a Driving Force in Infectious Diseases
|
Workshop
|
Elodie Ghedin
|
How We Rank